Xcout IntelInfoBionic, Inc.
InfoBionic, Inc. is a medical device manufacturer headquartered in Chelmsford, Massachusetts. The company specializes in developing advanced remote cardiac monitoring technologies and diagnostic software platforms. It provides healthcare providers with continuous ambulatory ECG solutions designed to improve patient care.
Subscribe to see InfoBionic, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
InfoBionic, Inc. at a glance
InfoBionic, Inc. is a healthcare it company headquartered in United States. Its most recent funding round raised $57.8M in September 2023.
InfoBionic, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $57.8M | — | |
| SEC Form D filing | $23.9M | — | |
| SEC Form D filing | $3M | — | |
| Growth | $8.2M | — | |
| Series B | $17M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
InfoBionic, Inc. competitors
A few of InfoBionic, Inc.'s closest competitors — see the full list of competitors and alternatives →
CardioComm Solutions, Inc. develops and sells advanced software and hardware products, and core laboratory reading services related to electrocardiogram (ECG) and ambulatory arrhythmia monitoring systems for medical and consumer markets globally. The company offers consumer health monitoring products, including GEMS mobile ECG, GEMS mobile RPM, HeartCheck CardiBeat Mobile ECG device, GlobalCardio, and HeartCheck SMART monitoring. It also provides healthcare professional monitoring products, such as GEMS Sirona, GEMS WIN, and Trident Pro 40L. CardioComm Solutions, Inc. was incorporated in 1989 and is headquartered in Toronto, Canada.
Cordio Medical develops medical-grade remote monitoring solutions that analyze voice samples through a smartphone application to detect health condition deterioration in near real-time. Its primary product, the Cordio HearO, uses mobile speech analysis to sense fluid accumulation associated with congestive heart failure and alerts healthcare professionals to early clinical decompensation.
Impact Vitals is a digital healthcare and medical technology company that develops artificial intelligence-based solutions to transform physiologic data into vital signs for patient monitoring. The company provides software and tools designed to help caregivers detect early patient deterioration and improve clinical outcomes in hospitals.
Established in 1987 and headquartered in Tel Aviv, Israel, SHL Telemedicine Ltd. is a global provider specializing in the development and distribution of individual remote healthcare solutions across Israel, Europe, and other international markets. The company's extensive product line includes a variety of advanced electrocardiogram (ECG) devices designed for personal use: Smartheart, a mobile 12-lead ECG capable of identifying heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter; Cardio'B, a portable 12-lead ECG unit; and the Cardio Beeper 12/12, a handheld device that transmits full ECG readings to a monitoring center. Beyond cardiac monitoring, SHL offers a suite of other remote diagnostic tools, such as a central communication module for relaying medical data from various devices to its telemedicine centers, TeleWeight for trans-telephonic weight tracking, TelePress for remote blood pressure measurements, TeleBreather for assessing lung function, and the TelePulse Oximeter for measuring blood oxygen saturation and pulse rate. These telemedicine services and devices are delivered to subscribers via both telephonic and internet communication channels. The company caters to a diverse range of clients, including individual patients, health insurance providers, hospitals, clinics, medical practitioners, and other healthcare organizations. SHL Telemedicine is also engaged in key collaborative research efforts. It partners with the Mayo Clinic to evaluate the efficacy of its FDA-approved SmartHeart in reducing emergency department visits, re-hospitalizations, and major adverse cardiovascular events in post-heart attack patients over a 90-day period. Additionally, the company is working with the Hebrew University of Jerusalem and the Hadassah Medical Center to create an artificial intelligence tool designed to predict future life-threatening cardiac incidents based on 12-Lead ECG monitoring.
Empatica Inc. is an MIT Media Lab spinoff company born in Cambridge, Massachusetts, operating in Healthcare, providing AI-enabled tools to advance forecasting, monitoring, research, and treatment. Empatica’s wearable devices include EmbracePlus and EmbraceMini, as well as earlier devices such as Embrace2 and E4. These wearables measure and track physiological signals such as heart rate, heart rate variability, electrodermal activity, motion and acceleration, skin temperature, and other indicators of autonomic nervous system activity. These data support applications in health monitoring, digita
Biofourmis partners with healthcare organizations and life science companies to offer solutions that expand care delivery. Their services include care delivery and life science solutions designed to transform organizations.
Get InfoBionic, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on InfoBionic, Inc. in Xcout Intel
- 5 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access